cytomegalovirus

(redirected from cytomegalovirus disease)
Also found in: Dictionary, Thesaurus, Medical.
Related to cytomegalovirus disease: CMV

cytomegalovirus

(sī'təmĕg'əlōvī`rəs), member of the herpesvirus family that can cause serious complications in persons with weakened immune systems and infants. A common virus, it is estimated that up to 80% of Americans carry cytomegalovirus by the time they reach adulthood. Most experience no symptoms or mild symptoms such as enlarged lymph nodes, low fever, and fatigue that may or may not be noticed. Cytomegalovirus is present in body fluids (saliva, semen, cervical secretions, and urine) and can be spread from person to person by sexual contact, kissing, or the sharing of food. It can also be transmitted from mother to fetus. The virus usually remains dormant in the body, but it can reactivate and cause serious symptoms in immunologically suppressed patients, such as those with AIDSAIDS
or acquired immunodeficiency syndrome,
fatal disease caused by a rapidly mutating retrovirus that attacks the immune system and leaves the victim vulnerable to infections, malignancies, and neurological disorders. It was first recognized as a disease in 1981.
..... Click the link for more information.
, or in infants whose immune systems are not yet fully developed. An estimated 25% of AIDS patients experience CMV infection, often in the form of a viral retinitis that can lead to blindness. Infants can become infected before birth when the mother becomes infected or experiences a recurrence during pregnancy. In a newborn, CMV can be life-threatening, and it can lead to later complications such as cerebral palsy, blindness, hearing problems, mental retardation, and learning disabilities. The antiviral drugs foscarnet and ganciclovir are used to keep active infections under control.

cytomegalovirus

[¦sīd·ō¦meg·ə·lō′vī·rəs]
(virology)
An animal virus belonging to subgroup B of the herpesvirus group; causes cytomegalic inclusion disease and pneumonia.
References in periodicals archive ?
Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation.
Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients.
Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation.
com/ ); and CytoGam(R), which is marketed for the prophylaxis against cytomegalovirus disease associated with transplantation of kidney, lung, liver, pancreas, and heart (see full prescribing information at http://www.
Together, this group covered the 250 organ transplantation centers in the United States for sale of CytoGam (Cytomegalovirus Immune Globulin Intravenous (Human), (CMV-IGIV)), a specialty immune globulin product developed for the attenuation of cytomegalovirus disease in kidney transplant recipients (see full prescribing information).
MedImmune currently markets its first product, CytoGam(R), for the prevention of cytomegalovirus disease in kidney transplant patients.
Among their perspectives are inhibiting HIV entry, helicase-primase inhibitors as a new approach to combating herpes simplex virus and varicella zoster virus, alkoxyalkyl ester pro-drugs of antiviral nucleoside phosphate and phosphonates, maribavir as a novel benzimidazole ribonucleoside for preventing and treating cytomegalovirus diseases, lethal mutagenesis as an unconventional approach to combating HIV, silencing viruses with antiviral RNAi, and neuraminidase inhibitors as anti-influenza agents.

Full browser ?